Comment on "Costs and consequences of cardiovascular toxicity due to Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia”
Revista Portuguesa de Cardiologia · 2026-11
DOI: 10.1016/j.repc.2026.06.009 ↗Kurz gefasst
Leserbrief in der Zeitschrift Revista Portuguesa de Cardiologia, 2026-11. Verfasst von Swarupanjali Padhi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, India. Electronic address: swarupanjali…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmaceutics, Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, India. Electronic address: swarupanjali.pharmacy@niet.co.in.
- Department of Community Medicine, Malla Reddy Institute of Medical Sciences, Malla Reddy Vishwavidyapeeth, Suraram, Hyderabad, Telangana, India.
- Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, Maharashtra, India.
Zitieren
APA
Padhi, S., Kokiwar, P. R., & Patel, J. (2026). Comment on "Costs and consequences of cardiovascular toxicity due to Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia”. Revista Portuguesa de Cardiologia. https://doi.org/10.1016/j.repc.2026.06.009
Vancouver
Padhi S, Kokiwar PR, Patel J. Comment on "Costs and consequences of cardiovascular toxicity due to Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia”. Revista Portuguesa de Cardiologia. 2026. doi:10.1016/j.repc.2026.06.009
BibTeX
@article{Padhi2026,
author = {Padhi, Swarupanjali and Kokiwar, Prashant Ramdas and Patel, Janvi},
title = {Comment on "Costs and consequences of cardiovascular toxicity due to Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia”},
journal = {Revista Portuguesa de Cardiologia},
year = {2026},
doi = {10.1016/j.repc.2026.06.009}
}
EUVIMED